SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age
SBC Medical has commenced in-house development of a DNA methylation test designed to estimate biological age, led by its AI and longevity subsidiary SBC AI Longevity Innovation. The initiative leverages regenerative medicine research from the Waqoo Group (TSE: 4937), a consolidated subsidiary, and SBC's clinic-scale MSO infrastructure, with a roadmap covering organ-specific mapping, non-invasive measurement, and Japan-specific cohort data.
Key figures
- Longevity market 2025
- approximately $800 billion
- Longevity market 2035 projection
- approximately $2 trillion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.